Stay updated on Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial
Sign up to get notified when there's something new on the Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial page.

Latest updates to the Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial page
- Check4 days agoChange DetectedRevision: v3.3.4 appears in the Study Documents section, replacing the previous v3.3.3 entry. This is a minor metadata update to the document versions listed on the page.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedAdded a dedicated Locations section listing Florida and Georgia, and removed the separate Florida Locations and Georgia Locations blocks. Revision updated to v3.3.3.SummaryDifference0.3%

- Check53 days agoChange DetectedAdded a note that PubMed publications are automatically filled from PubMed and may not be about the study; updated revision to v3.3.2. Removed the previous wording stating that publications come from PubMed and are automatically created by ClinicalTrials.gov Identifier (NCT Number) and the older revision reference v3.2.0.SummaryDifference0.1%

- Check61 days agoChange DetectedRemoved the government funding lapse notice from the top of the page.SummaryDifference0.4%

- Check75 days agoChange DetectedResults First Posted date (2024-12-27) and updated Study Record Dates were added, and a PubMed publication (Nat Med 2023) is linked. The page now includes the study's enrollment (36) and access to the protocol and consent forms.SummaryDifference0.4%

- Check104 days agoChange Detected- Added a government-funding notice about potential delays and updated operating status guidance, and a major version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference2%

Stay in the know with updates to Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial page.